A5006119573- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Venous Thromboembolism Diagnosis and Management
- Cancer-related gene regulation
- Platelet Disorders and Treatments
- Central Venous Catheters and Hemodialysis
- Sepsis Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Acute Myocardial Infarction Research
- Emergency and Acute Care Studies
- Hemostasis and retained surgical items
- Intracranial Aneurysms: Treatment and Complications
- Sports Performance and Training
- Vascular anomalies and interventions
- Moyamoya disease diagnosis and treatment
- Pharmacological Effects and Toxicity Studies
- Translation Studies and Practices
- Vasculitis and related conditions
- Winter Sports Injuries and Performance
- MicroRNA in disease regulation
- Adolescent and Pediatric Healthcare
- Healthcare cost, quality, practices
- Extracellular vesicles in disease
University of Colorado Anschutz Medical Campus
2015-2024
University of Colorado Denver
2014-2023
Children's Hospital Colorado
2014-2023
Center for Cancer and Blood Disorders
2020
Abstract The Joint Outcome Study (JOS), a randomized controlled trial, demonstrated that children with severe hemophilia A (HA) initiating prophylactic factor VIII (FVIII) prior to age 2.5 years had reduced joint damage at 6 compared those treated episodic FVIII for bleeding. Continuation (JOS-C) evaluated early vs delayed prophylaxis effects on long-term health, following JOS participants 18 in an observational, partially retrospective study. Index magnetic resonance imaging (MRI) scores of...
Background The National Hemophilia Foundation (NHF) conducted extensive all-stakeholder inherited bleeding disorder (BD) community consultations to inform a blueprint for future research. Sustaining and expanding the specialized comprehensive Treatment Center care model, better serve all people with BDs (PWIBD), increasing equitable access optimal health emerged as top priorities.Research Design Methods NHF, American Thrombosis Hemostasis Network (ATHN), convened multidisciplinary expert...
Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks side effects compared to products.
Abstract Introduction The Joint Outcome Study (JOS) demonstrated that previously untreated children with severe haemophilia A treated prophylactic factor VIII (FVIII) concentrate had superior joint outcomes at age 6 years compared to those episodically for bleeding. However, variation in outcome within each treatment arm was not well explained. Aim In this study, we sought better understand participants of the JOS. Methods We evaluated influence FVIII half‐life, adherence, constitutional...
Abstract Background There is need for validated outcome measures postthrombotic syndrome (PTS) following pediatric venous thromboembolism (VTE), with a focus on quality of life (QoL). Aims This article assesses reliability and validity two PTS QoL scales children lower extremity VTE. Methods Pediatric patients VTE were recruited from three thrombosis clinics. The Manco–Johnson (MJ) the modified Villalta (MV) compared each other generic health-related QoL, PedsQL, newly developed...
Emicizumab, the bispecific human antibody that mimics factor VIII by bringing together activated IX and X, has significantly improved care for persons with hemophilia A (HA), providing a subcutaneous means of prophylaxis is given less frequently than intravenous infusions. The HAVEN studies,1.Oldenburg J. Mahlangu J.N. Kim B. et al.Emicizumab in inhibitors.N Engl J Med. 2017; 377: 809-818https://doi.org/10.1056/NEJMoa1703068Crossref PubMed Scopus (585) Google Scholar, 2.Young G. Liesner R....